Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?
Abdurrahmaan Ali Suei Elbuzidi, ECMO and Critical Care Consultant at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Journal of Cardiothoracic and Vascular Anesthesia, adding:
“Excited to share that our latest systematic review and meta-analysis has been published:
‘Clinical Outcomes of Different Heparin Anticoagulation Monitoring Targets in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.’
This work explores an important and ongoing challenge in ECMO care:
What is the optimal anticoagulation monitoring target?
Despite widespread use of unfractionated heparin in ECMO, significant variability remains in monitoring strategies (ACT, aPTT, anti-Xa, and others), with potential implications for bleeding, thrombosis, and overall patient outcomes.
Our review aimed to synthesize the available evidence and evaluate how different monitoring targets may influence clinical outcomes.
Proud to have collaborated with an outstanding multidisciplinary team of colleagues on this project.Special thanks to all co-authors for their dedication and contributions.
Looking forward to continued research that helps refine anticoagulation strategies and improve outcomes for ECMO patients.”
Title: Clinical Outcomes of Different Heparin Anticoagulation Monitoring Targets in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-analysis
Authors: Alaa Rahhal, Ans Alamami, Rabee Tawel, Ahmed Shebani, Hassan Fahed El Daezli, Abdurrahmaan Elbuzidi, Nadir Kharma, Amr Omar, Ahmed Labib Shehatta
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 12:34Kellie Machlus: Animal Models Driving Progress in Thrombosis Research
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management